Salem, Ahmed Hamed

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

Wei, A. H., Strickland, S. A., Hou, J.-Z., Fiedler, W., Lin, T. L., Walter, R. B., Enjeti, A., Tiong, I. S., Savona, M., Lee, S., et al. (2019) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 692

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

Jones, J. A., Mato, A. R., Wierda, W. G., Davids, M. S., Choi, M., Cheson, B. D., Furman, R. R., Lamanna, N., Barr, P. M., Zhou, L., et al. (2018) · The Lancet Oncology

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 383

Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade

Kohlhapp, F. J., Haribhai, D., Mathew, R., Duggan, R., Ellis, P. A., Wang, R., Lasater, E. A., Shi, Y., Dave, N., Riehm, J. J., et al. (2021) · Cancer Discovery

Cancer Immunotherapy and BiomarkersCell death mechanisms and regulation

Cited by 126